Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with T-Cell Malignancies: Final Results of a Phase I/II Trial

Blood (2023) 142 (Supplement 1): 184.

https://doi.org/10.1182/blood-2023-190213

Published: 2023

Journal Articles

Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL

Kerry A Rogers, Eric McLaughlin, Lai Wei, Seema A Bhat, Arianna Crouse, Michael R. Grever, Dan Jones, Adam S Kittai, Gerard Lozanski, Mollie Moran, Mark Reid, Ellen J Sass, Swetha Suresh, John C. Byrd, Jennifer A. Woyach

Blood (2023) 142 (Supplement 1): 1899.

https://doi.org/10.1182/blood-2023-180294

Published: 2023

Journal Articles

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial

Blood (2022) 140 (Supplement 1): 1885–1886.

https://doi.org/10.1182/blood-2022-169336

Published: 2022

Journal Articles

Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

Kerry A. Rogers, Eric McLaughlin, Lai Wei, Mirela Iulia Anghelina, Mir Khader Ali, Leslie A. Andritsos, Evgeny Arons, James S. Blachly, Timothy G. Call, S. Percy Ivy, Lacey James-Echenique, Jeffrey A. Jones, Robert J. Kreitman, Gerard Lozanski, Farhad Ravandi, Charles A. Schiffer, William E. Carson, III, Michael R. Grever

Blood (2022) 140 (Supplement 1): 6494–6495.

https://doi.org/10.1182/blood-2022-165795

Published: 2022

Journal Articles

Romidepsin in Conditioning and Maintenance Mitigates Relapse Risk and Enhances NK-Cell Cytotoxicity in Patients Receiving Allogeneic Stem Cell Transplant for Aggressive T-Cell Malignancies: Results of a Phase I/II Clinical Trial

Blood (2021) 138 (Supplement 1): 553.

https://doi.org/10.1182/blood-2021-152833

Published: 2021

Journal Articles

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Blood (2021) 137 (25): 3473–3483.

https://doi.org/10.1182/blood.2020009688

Published: 2021

Includes: Supplemental data

Journal Articles

Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL

Jennifer Woyach, MD, Shanmugapriya Thangavadivel, PhD, David Weiss, Lai Wei, PhD, Eric McLaughlin, MS, Kerry Rogers, Seema A. Bhat, MD, Michael R. Grever, MD, Michael Keller, Matthew Dort, Gerard Lozanski, MD, Barbara Andersen, PhD, John C. Byrd, MD, Farrukh T. Awan, MD

Blood (2019) 134 (Supplement_1): 1759.

https://doi.org/10.1182/blood-2019-131099

Published: 2019

Journal Articles

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Kerry A Rogers, MD, Lai Wei, PhD, Seema A. Bhat, MD, Dan Jones, MD PhD, Erlene K. Seymour, MD, Deborah M. Stephens, DO, J Christine Ye, MDMSc, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 3049.

https://doi.org/10.1182/blood-2019-125360

Published: 2019

Journal Articles

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

David A. Bond, MD, Vedat Yildiz, Lai Wei, PhD, Lapo Alinari, MD PhD, Basem M. William, MRCP,MD, Jonathan E. Brammer, MD, Beth A. Christian, MD, Kristie A. Blum, MD, Kami J. Maddocks, MD

Blood (2019) 134 (Supplement_1): 4091.

https://doi.org/10.1182/blood-2019-130539

Published: 2019

Journal Articles

Hepatitis E Virus Infection after Haploidentical Hematopoietic Stem Cell Transplantation:Incidence and Clinical Course

Fei-Fei Tang, Xiao-Dong Mo, Yu Wang, Chen-Hua Yan, Yu-Hong Chen, Huan Chen, Wei Han, Ying-Jun Chang, Hai-Ying Zhang, Yan-Di Xie, Hui Ma, Lai Wei, Lan-Ping Xu, Xiao-Jun Huang, Xiaohui Zhang, MD

Blood (2018) 132 (Supplement 1): 5734.

https://doi.org/10.1182/blood-2018-99-113953

Published: 2018

Journal Articles

Atorvastatin As an Adjunct Therapy in Patients with Acute Venous Thromboembolism

Tzu-Fei Wang, MD, Melanie Heinlein, Amanda P. Waller, PhD, Lai Wei, PhD, Bryce A. Kerlin, MD

Blood (2017) 130 (Supplement 1): 1099.

https://doi.org/10.1182/blood.V130.Suppl_1.1099.1099

Published: 2017

Journal Articles

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Farrukh T. Awan, MD MS, Shanmugapriya Thangavadivel, PhD, David Weiss, Lai Wei, PhD, Jennifer A. Woyach, MD, Kerry A. Rogers, MD, Jeffrey Jones, MD, Leslie Andritsos, MD, Natarajan Muthusamy, DVM,PhD, Barbara Andersen, PhD, John C. Byrd, MD

Blood (2017) 130 (Supplement 1): 1748.

https://doi.org/10.1182/blood.V130.Suppl_1.1748.1748

Published: 2017

Journal Articles

A Phase I Study of Gemcitabine and Bendamustine in Relapsed/Refractory Hodgkin Lymphoma

Jonathon B. Cohen, MD, Lai Wei, PhD, Kami J. Maddocks, MD, Leonard T. Heffner, MD, Amelia Langston, MD, Christopher Flowers, MD, Steven M. Devine, MD, Kristie A. Blum, MD

Blood (2015) 126 (23): 1496.

https://doi.org/10.1182/blood.V126.23.1496.1496

Published: 2015

Journal Articles

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma

Kami Maddocks, Beth Christian, Samantha Jaglowski, Joseph Flynn, Jeffery A. Jones, Pierluigi Porcu, Lai Wei, Cynthia Jenkins, Gerard Lozanski, John C. Byrd, Kristie A. Blum

Blood (2015) 125 (2): 242–248.

https://doi.org/10.1182/blood-2014-08-597914

Published: 2015

Journal Articles

Immunosuppressive Treatment Combined with Nucleoside Analogues Is Superior to Nucleoside Analogues Alone in the Treatment of Severe Thrombocytopenia in Patients with Cirrhosis-Associated with Hepatitis B in China: A Multicenter, Observational Study

Xiao-Hui Zhang, MD, PhD, Ru Feng, Lan-ping Xu, Qian Jiang, Hao Jiang, Hai-xia Fu, Hui Liu, Ting Niu, Xin Wang, Jian-da Hu, Ming Jiang, Zhao Wang, Jing-wen Wang, Hui Ma, Yan-di Xie, Xiao-lu Zhu, Hao Wang, Lai Wei, Xiao Jun Huang

Blood (2014) 124 (21): 2778.

https://doi.org/10.1182/blood.V124.21.2778.2778

Published: 2014

Journal Articles

A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin’s Lymphoma (HL)

Beth Christian, MD, Lai Wei, Jennifer Sexton, Samantha M. Jaglowski, MD MPH, Steven M. Devine, MD, Todd A. Fehniger, MD PhD, Nina Wagner-Johnston, Nancy L. Bartlett, MD, Kristie A. Blum, MD

Blood (2014) 124 (21): 3099.

https://doi.org/10.1182/blood.V124.21.3099.3099

Published: 2014

Journal Articles

Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial,

Kristie A. Blum, MD, Lai Wei, Jeffrey A. Jones, MD, MPH, Leslie A Andritsos, MD, Joseph M. Flynn, DO, MPH, Nyla A. Heerema, PhD, Xiaoxia Yang, Darlene Rozewski, Mitchell Phelps, Ph.D., Amy J Johnson, PhD, Michael R. Grever, M.D., John C. Byrd, MD

Blood (2011) 118 (21): 3910.

https://doi.org/10.1182/blood.V118.21.3910.3910

Published: 2011

Journal Articles

Methylation Profiling of Mediastinal Gray Zone Lymphoma Reveals a Distinctive Signature with Elements Shared by Classical Hodgkin's Lymphoma and Mediastinal Large B-Cell Lymphoma

Franziska C. Eberle, Jaime Rodriguez-Canales, Lai Wei, Jeffrey C. Hanson, J. Keith Killian, Hong-Wei Sun, Lisa G. Adams, Stephen M. Hewitt, Wyndham H. Wilson, Paul S. Meltzer, Louis M. Staudt, Michael R. Emmert-Buck, Stefania Pittaluga, Elaine S. Jaffe

Blood (2010) 116 (21): 747.

https://doi.org/10.1182/blood.V116.21.747.747

Published: 2010

Journal Articles

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Sarah E. M. Herman, Amber L. Gordon, Amy J. Wagner, Nyla A. Heerema, Weiqiang Zhao, Joseph M. Flynn, Jeffrey Jones, Leslie Andritsos, Kamal D. Puri, Brian J. Lannutti, Neill A. Giese, Xiaoli Zhang, Lai Wei, John C. Byrd, Amy J. Johnson

Blood (2010) 116 (12): 2078–2088.

https://doi.org/10.1182/blood-2010-02-271171

Published: 2010

Journal Articles

A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma

Kristie A. Blum, MD, Robert A. Baiocchi, Lapo Alinari, Thomas S. Lin, Pierluigi Porcu, Jeffrey Jones, Joseph Flynn, William Hicks, Margaret S. Lucas, Lai Wei, Jeffrey S. Johnston, John C. Byrd

Blood (2008) 112 (11): 3053.

https://doi.org/10.1182/blood.V112.11.3053.3053

Published: 2008

NARROW

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with T-Cell Malignancies: Final Results of a Phase I/II Trial

Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial

Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

Romidepsin in Conditioning and Maintenance Mitigates Relapse Risk and Enhances NK-Cell Cytotoxicity in Patients Receiving Allogeneic Stem Cell Transplant for Aggressive T-Cell Malignancies: Results of a Phase I/II Clinical Trial

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

Hepatitis E Virus Infection after Haploidentical Hematopoietic Stem Cell Transplantation:Incidence and Clinical Course

Atorvastatin As an Adjunct Therapy in Patients with Acute Venous Thromboembolism

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

A Phase I Study of Gemcitabine and Bendamustine in Relapsed/Refractory Hodgkin Lymphoma

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma

Immunosuppressive Treatment Combined with Nucleoside Analogues Is Superior to Nucleoside Analogues Alone in the Treatment of Severe Thrombocytopenia in Patients with Cirrhosis-Associated with Hepatitis B in China: A Multicenter, Observational Study

A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin’s Lymphoma (HL)

Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial,

Methylation Profiling of Mediastinal Gray Zone Lymphoma Reveals a Distinctive Signature with Elements Shared by Classical Hodgkin's Lymphoma and Mediastinal Large B-Cell Lymphoma

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only